Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 405-408

  Hardy, Thomas A ^a   Marquez, Eva ^a   Kryzhanovskaya, Ludmila ^a   Taylor, Cindy C ^a   Cavazzoni, Patrizia ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN B; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; FLUPHENAZINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES; WAIST-HIP RATIO; WEIGHT GAIN;

EID: 33746882758     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227705.56870.06     Document Type: Article

References (23)

1. US Department of Health and Human Services (DHHS). National Center for Health Statistics. NHANES III reference manuals and reports (CD-ROM). Hyattsville, MD: Centers for Disease Control and Prevention; 1996.
2. Sasaki J, Kumagae G, Sata T, et al. Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis. 1984;51:163-169.
3. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865.
4. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
5. Bouchard RH, Demers MF, Simoneau I, et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol. 2001;21:110-111.
6. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
7. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
8. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987;28:613-628.
9. Watanabe N, Taniguchi T, Taketoh H, et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999;22:152-156.
10. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487-1495.
11. Levene H. Robust tests for equality of variances. In: Olkin I, Ghurye SG, Hoeffding W, et al, eds. Contributions to Probability and Statistics. Palo Alto, CA: Stanford University Press; 1960:278-292.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
13. Yeni-Komshian H, Carantoni M, Abbasi F, et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-175.
14. Eberly LE, Stamler J, Neaton JD, for the Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003;163:1077-1083.
15. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64:839-883.
16. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
17. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64:575-579.
18. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021-1026.
19. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-296.
20. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462.
21. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
22. McCreadie RG, for the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534-539.
23. Carroll M, Sempos C, Briefel R, et al. Serum Lipids of Adults 20-74 Years: United States, 1976-80. Vital Health Stat. Hyattsville, Maryland: National Center for Health Statistics; 1993;11(242).